Skeletal muscle AMPK is essential for the maintenance of FNDC5 expression by Lally, James S. V. et al.
ORIGINAL RESEARCH
Skeletal muscle AMPK is essential for the maintenance of
FNDC5 expression
James S. V. Lally1, Rebecca J. Ford1, Jasper Johar1, Justin D. Crane1, Bruce E. Kemp2 & Gregory R.
Steinberg1,3
1 Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2 St. Vincent’s Institute of Medical Research and Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia
3 Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
Keywords
AMPK, exercise, FNDC5, skeletal muscle.
Correspondence
Gregory R. Steinberg, Division of
Endocrinology and Metabolism, Department
of Medicine, Rm HSC 4N63, McMaster
University, 1280 Main St. West, Hamilton,
Ontario, L8N 3Z5 Canada.
Tel: 905-521-2100; ext. 21691
Fax: 905-777-7856
E-mail: gsteinberg@mcmaster.ca
Funding Information
This work was supported by grants and
fellowships from the Australian National
Health and Medical Research Council (BEK
and GRS) the Canadian Institutes of Health
Research and the Natural Sciences and
Engineering Research Council (GRS) and the
Australian Research Council and the Victorian
Government Operational Infrastructure
Support Scheme (BEK). GRS holds the
Canada Research Chair in Metabolism and
Obesity and the J. Bruce Duncan Chair in
Metabolic Diseases.
Received: 29 December 2014; Revised: 17
February 2015; Accepted: 19 February 2015
doi: 10.14814/phy2.12343
Physiol Rep, 3 (5), 2015, e12343,
doi: 10.14814/phy2.12343
Abstract
Fibronectin type III domain-containing protein 5 (FNDC5) expression is con-
trolled by the transcriptional co-activator, peroxisome proliferator-activated
receptor gamma, coactivator 1 alpha (PGC1a). FNDC5 expression has been
shown to be increased in muscle in response to endurance exercise in some
but not all studies, therefore a greater understanding of the mechanisms con-
trolling this process are needed. The AMP-activated protein kinase (AMPK) is
activated by exercise in an intensity dependent manner and is an important
regulator of PGC1a activity; therefore, we explored the role of AMPK in the
regulation of FNDC5 using AMPK b1b2 double muscle-null mice (AMPK
DMKO), which lack skeletal muscle AMPK activity. We found that FNDC5
expression is dramatically reduced in resting muscles of AMPK DMKO mice
compared to wild-type littermates. In wild-type mice, activating phosphoryla-
tion of AMPK was elevated immediately post contraction and was abolished
in muscle from AMPK DMKO mice. In contrast, PGC1a was increased in
both wild-type and AMPK DMKO mice 3 h post contraction but FNDC5
protein expression was not altered. Lastly, acute or chronic activation of
AMPK with the pharmacological AMPK activator AICAR did not increase
PGC1a or FNDC5 expression in muscle. These data indicate that skeletal
muscle AMPK is required for the maintenance of basal FNDC5 expression.
Introduction
The health benefits of regular exercise are undisputed but
the molecular mechanisms mediating the effects remain
unclear. It has been suggested that secreted factors from
skeletal muscle (myokines) may modulate some of the
beneficial health effects of exercise (Pedersen and Febbra-
io 2012). Recently a novel myokine encoded by the fibro-
nectin type III domain-containing protein 5 (FNDC5)
gene that gives rise to a released fragment (amino acids
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29–140) termed irisin, was found to be produced in
response to peroxisome proliferator-activated receptor c
co-activator-1a (PGC-1a) activation following exercise
training (Bostrom et al. 2012). A number of papers have
begun to provide valuable data on FNDC5/irisin includ-
ing its structure (Schumacher et al. 2013), signaling in
white adipose tissue (Zhang et al. 2014), participation in
the adaptation to cold, (Lee et al. 2014), and importance
in regulating brain derived brain-derived neurtrophic fac-
tor (BDNF) production in the hippocampus (Wrann
et al. 2013). Unfortunately, initial exuberance surround-
ing irisin has led to an explosion of clinically based stud-
ies that rely heavily the ability to detect irisin in
circulation, which now appears questionable (Albrecht
et al. 2015) and have revealed few mechanistic insights.
How exercise mediates changes in FNDC5 expression is
not fully understood, and notably irisin expression has
not been observed during all types of exercise, especially
in humans (Pekkala et al. 2013; Raschke et al. 2013).
Therefore, a greater understanding of factors controlling
FNDC5/irisin expression is warranted.
AMP-activated protein kinase (AMPK) is a multi-
substrate kinase that is activated in skeletal muscle dur-
ing exercise (Steinberg and Jorgensen 2007; Richter and
Ruderman 2009). AMPK exists as a heterotrimeric pro-
tein composed of a (a1 & a2), b (b1 & b2) and c (c1,
c2 & c3) subunits (Steinberg and Kemp 2009). AMPK
activation is linked to PGC-1a function, as AMPK can
directly phosphorylate PGC1a, a process that is impor-
tant for auto-regulatory mechanism by which PGC-1a
perpetuates its own expression (J€ager et al. 2007; O’Ne-
ill et al. 2013). We have recently generated mice lacking
muscle AMPK activity through targeted deletion of
both AMPK b1 and b2 subunits (O’Neill et al. 2011).
AMPK double b muscle knock-out mice (AMPK
DMKO) have no detectable muscle AMPK activity and
are characterized by dramatic reductions in exercise
capacity and muscle mitochondrial content. Given the
intimate connection between endurance exercise, AMPK
and PGC1a activity we hypothesized that FNDC5 may
be reduced in AMPK DMKO mice. We find that mus-
cle FNDC5 expression is lower in muscle of AMPK
DMKO mice.
Materials and Methods
Animals
AMPK DMKO mice have been described previously
(O’Neill et al. 2011). AMPK DMKO and wild-type litter-
mates were housed in specific pathogen free micro-isola-
tor cages maintained under a 12 h light/dark cycle at a
constant temperature of 23°C. Mice had access to stan-
dard chow and water ad libitum. All of the experiments
performed in this study were approved by the McMaster
University Animal Research Ethics Board.
Treadmill exercise
Before the treadmill running experiments, mice were
allowed to acclimatize to the treadmill apparatus as
described previously (O’Neill et al. 2011). Maximal run-
ning speed was established by allowing the mice to run at
10 m/min for 2 min with an incline of 5 degrees. The
speed of the treadmill was then increased by 1 m/min
every 2 min until mice could not be prompted to con-
tinue running. The following week mice underwent an
acute, submaximal bout of exercise. Mice were run at
10 m/min for two minutes, followed by an increase in the
treadmill speed to 70% of maximal running velocity until
volitional exhaustion.
In situ contraction experiments
In situ contraction experiments were performed as we
have described previously (Dzamko et al. 2008), with
some modifications. Mice were anesthetized using inhala-
tion anesthetic (1–2% isoflurane in O2), the tibialis ante-
rior muscle was surgically exposed, the distal tendon
secured using a piece of 5.0 suture and severed from its
attachment point. Mice were mounted to an 809B in situ
Mouse Apparatus platform (Aurora Scientific Inc., Aur-
ora, ON, Canada) maintained at constant temperature of
33°C. Using the free end of the suture, the tendon was
attached to a 300C dual mode muscle lever system (Aur-
ora Scientific) and the muscle was stimulated to contract
via two small platinum hook electrodes place around sci-
atic nerve. Optimal muscle length was determined by
administering single electrical pulses (200 ms at 2–3 mA)
while lengthening the muscle until optimal twitch force
was attained. The muscle was stimulated 400 times at
10 hz for 0.5 sec with 3.7 sec rest between contractions.
The amperage was adjusted between 1.5 and 4.0 mA to
maintain a target force of 250 mN. Upon completion, the
tibialis anterior muscle was excised and flash frozen in
liquid nitrogen either immediately or 3 h post contraction
and stored at 80°C for subsequent molecular analysis.
AICAR administration
Mice received a daily injection of saline (control) or AI-
CAR (500 mg/kg) for a 2-week period. Blood glucose was
measured on whole blood using a handheld glucometer
one hour after the first injection. One hour following the
final injection the mice were anesthetized using ketamine/
xylanzine as before, tissues were collected and flash frozen
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using liquid nitrogen and stored at 80°C for subsequent
molecular analysis.
Protein and mRNA analysis
For real time PCR analysis, total RNA was extracted from
8 to 20 mg of muscle tissue using a combination Trizol
reagent (Life Technologies Inc., Burlington, ON, Canada)
and RNeasy mini kit (Qiagen, Toronto, ON, Canada).
cDNA was generated from 0.5 lg of total RNA with
Superscript III reverse transcriptase (Invitrogen) using
random primers. The levels of Fndc5, Pgc1a and Tbp
(TATA-binding protein) were determined using TaqMan
assays on demand (Invitrogen). Relative RNA abundance
was calculated using the DDCT method as we have
described previously (O’Neill et al. 2011) using Tbp as an
endogenous control.
Protein abundance was determined using Western blot
analysis as we have described previously (O’Neill et al.
2011) using the following commercially available antibod-
ies: Acetyl-CoA Carboxylase (ACC) (#3676), ACC pSer79
(#3661), AMPK pan a (#2532), AMPK pThr172 (#2532),
GAPDH (#5174), all from Cell Signaling Technology,
Inc., Danvers, MA and FNDC5 using Irisin (42–112)
purified IgG antibody (Phoenix Pharmaceuticals, Burlin-
game, CA).
Statistics
All data are expressed as means plus or minus the SEM
Statistical analysis was carried out using Graphpad Prism6
software; GraphPad Software, Inc., La Jolla, CA. Student’s
t-test or two-way ANOVA with Fisher’s LSD post-hoc test
were used where appropriate. Significant differences were
reported if P ≤ 0.05.
Results
FNDC5 expression is lower in AMPK DMKO
muscle and is not affected by exercise or
muscle contraction
We examined whether an acute bout of treadmill exercise
can affect FNDC5 expression and whether AMPK might
be important. A progressive treadmill exercise test was
used to establish the maximum running speed of wild-
type and AMPK DMKO mice. In line with previous find-
ings (O’Neill et al. 2011), AMPK DMKO were severely
exercise intolerant (wild-type = 26 m/min vs AMPK
DMKO = 14 m/min, P < 0.0001, Fig. 1A). The following
week mice were either rested or performed a single bout
of exhaustive exercise at 70% of their relative maximum
speed (18 m/min for wild-type mice vs. 10 m/min for
AMPK DMKO), which was sufficient to activate AMPK
and phosphorylate its downstream substrate ACC at the
Ser212 site in skeletal muscle tissue from wild-type but
not AMPK DMKO mice (Fig. 1B and C). We found that
FNDC5 protein expression was reduced in AMPK DMKO
mice both at rest and following treadmill exercise
(Fig. 1D). Despite robust AMPK activation there was no
increase in skeletal muscle FNDC5 protein levels immedi-
ately following exercise in wild-type mice (Fig. 1D). These
data indicate that AMPK is important for controlling
basal/resting muscle FNDC5 expression but a single bout
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Figure 1. Expression of FNDC5 is lower in muscle tissue from AMPK DMKO mice compared to wild-type mice but is unaltered after exhaustive
treadmill exercise. (A) The maximum speed attained during a progressive treadmill running exercise capacity test in wild-type and AMPK DMKO
mice. AMPK alpha pThr172 (B) and ACC2 pSer212 (C) phosphorylation levels and FNDC5 protein content (D) at rest (Rest) or immediately
following exercise (Post Ex) in tibialis anterior muscle tissue (N = 3–5). Error bars represent standard error of the mean. ND, not detectable.
*Significantly different from wild-type, P < 0.05. **Significantly different from wild-type Rest.
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of treadmill exercise that activates AMPK is insufficient to
increase FNDC5 protein expression.
We next developed an in situ approach that allows for
the precise measurement of the force of each contraction,
while maintaining blood flow and neural inputs to con-
tracting muscle. The tibialis anterior muscle was stimu-
lated to contract 400 times and the force output was
precisely matched between wild-type and AMPK DMKO
mice over approximately 30 min (Fig. 2A). Muscles were
collected at rest, immediately post contraction or they
were allowed to recover in situ for 3 h after completion
of the contraction series.
In wild-type mice AMPKa activating Thr172 phosphor-
ylation was increased immediately post-contraction (4-
fold, P < 0.001, Fig. 2B) and had returned to basal levels
3 h later. AMPK DMKO mice had no detectable AMPK
Thr172 phosphorylation at any time point consistent with
our previous observations indicating the lack of skeletal
muscle AMPK activity in this mouse model (O’Neill et al.
2011). Phosphorylation of the AMPK substrate ACC2 at
Ser 212 was elevated post contraction in wild-type but
not in AMPK DMKO muscle tissue (Fig. 2C). Impor-
tantly, the increase in ACC phosphorylation in WT mice
was comparable to that elicited following treadmill
running (Fig. 1C). There was no difference in PGC1a
expression between genotypes at rest or immediately
post-contraction, however 3 h later PGC1a expression
was increased in contracted tibialis anterior muscle from
both wild-type and AMPK DMKO mice (6- to 8-fold,
P < 0.001, Fig. 2D). The increase was blunted in muscle
from AMPK DMKO animals, indicating that AMPK inde-
pendent pathways are important for controlling PGC1a
expression during muscle contractions (Fig. 2D). Despite
the robust increases in Pgc1a mRNA three hours post
contraction there was no increase in Fndc5 mRNA or
protein content (Fig. 2E and F). Importantly, FNDC5
expression remained lower in AMPK DMKO mice before,
immediately after and 3 h post muscle contractions
(Fig. 2E and F).
Acute or chronic administration of AICAR
does not affect FNDC5 expression
Given the regulation of FNDC5 expression by AMPK in rest-
ing but not contracting muscle we next tested whether phar-
macological activation of AMPK using acute or chronic
administration of the AMPK agonist 5-Aminoimidazole-4-
carboxamide ribonucleotide (AICAR) could increase FNDC5
levels in wild-type mice. Acute AICAR injection increased
AMPK phosphorylation of ACC2 at Ser212 (Fig. 3A, 2.6-
fold, P < 0.001) and lowered blood glucose after 1 h in
agreement with previous studies (Steinberg et al. 2010;
Fig. 3B). Chronic daily administration of AICAR over a 2-
week period did not alter Pgc1a or Fndc5 mRNA content
(Fig. 3C) or FNDC5 protein levels (Fig. 3D) in tibialis ante-
rior muscle.
Discussion
FNDC5/irisin was first characterized as a muscle
secreted factor regulated by PGC1a that was increased
in response to endurance exercise training. Despite
extensive examinations of the metabolic functions of
this novel protein few studies have examined the mech-
anisms by which acute exercise/muscle contractions
increase FNDC5 expression. While several reports have
questioned whether skeletal muscle FNDC5 expression
is increased following exercise (Timmons et al. 2012;
Pekkala et al. 2013; Raschke et al. 2013) there is emerg-
ing evidence that during high-intensity endurance exer-
cise that FNDC5 expression is increased (Huh et al.
2014). However, the factors upstream of PGC1a that
control FNDC5 expression in response to muscle con-
tractions/exercise have yet to be delineated.
We found that muscle-specific deletion of AMPK
lowered basal expression levels of FNDC5 in tibialis
anterior muscle. Thus our data establish a novel linkage
between skeletal muscle AMPK and the maintenance of
basal FNDC5 expression. This may involve an AMPK-
PGC1a-FNDC5 regulatory axis, as AMPK has been
shown to act upstream of PGC1a (O’Neill et al. 2013).
Previous work has also suggested a relationship between
AMPK-PGC1a-FNDC5 as a consequence of whole-body
myostatin deletion (Shan et al. 2013). This group
showed that AMPK inhibition through treatment with
compound C, elicited a decrease in FNDC5 expression
in myostatin null myotubes. It is notable that com-
pound C also inhibits more than 10 other protein kin-
ases with greater or equal efficacy to AMPK and
importantly many of these protein kinases are known
regulators of PGC1a activity (Bain et al. 2007), there-
fore further studies confirming these effects in genetic
models are warranted. One potential confounding factor
when using transgenic models with alterations in major
metabolic regulatory nodes such as AMPK is that the
animals may have reduced activity levels. In such cases
muscle disuse can drive phenotypic changes that cannot
be solely attributed to alterations in AMPK. It is
important to note that previous work from our labora-
tory has shown that AMPK DMKO do not have
reduced activity levels (O’Neill et al. 2011) suggesting
that the reduction in FNDC5 expression observed in
AMPK DMKO muscle tissue is unlikely to be due to
reduced physical activity. Ideally future studies will
investigate whether an acute/inducible reduction in
AMPK expression also lowers FNDC5 expression.
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Skeletal muscle AMPK is activated in response to
energetic stresses such as endurance exercise which dis-
rupts the adenylate charge of the cell (Steinberg and
Jorgensen 2007). Consistent with this idea AMPK is
activated in an intensity dependent manner (Fujii et al.
2000; Wojtaszewski et al. 2000; Chen et al. 2003) and is
essential for allowing animals to perform endurance
treadmill running (O’Neill et al. 2011). Given the limi-
tation of the treadmill exercise experiments as a result
of the exercise intolerance of the AMPK DMKO mice
we proceeded to do experiments under more controlled
settings in which absolute contraction intensities could
be matched between genotypes. Sustained and force-
matched in situ contraction caused robust and expected
AMPK activation and increases in Pgc1a expression in
wild-type and AMPK DMKO mice. To our knowledge
this is the first evidence that contraction-stimulated
increases in Pgc1a occur in mice genetically lacking
both AMPK subunits. The robust elevation in Pgc1a
mRNA levels post-exercise is well documented (Hilde-
brandt et al. 2003), and temporal and intensity related
changes occur in both rodents (Tadaishi et al. 2011)
and humans (Mathai et al. 2008; Perry et al. 2010).
Importantly, this occurred after a matched bout of con-
traction sufficient to activate AMPK in wild-type mur-
ine muscle, indicating that AMPK is required for full
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PGC1a induction, at least at modest intensities; an idea
consistent with the notion that AMPK mediates PGC1a
autoregulation (Handschin et al. 2003).
Interestingly, despite this robust increase in Pgc1a
expression there was no change in FNDC5 mRNA or
protein expression in skeletal muscle following in situ
contractions. The reason for the dichotomy between Pgc1a
and FNDC5 expression in response to muscle contractions
is not known. However it appears not to be related to the
more modest increase in AMPK activity, as ACC phos-
phorylation was comparable in wild-type mice following
either treadmill exercise (Fig. 2C) or in situ muscle con-
traction (Fig. 3C). A number of other upstream kinases
have been implicated in regulating PGC1a activity includ-
ing p38 mitogen activated protein kinase (Puigserver et al.
2001; Akimoto et al. 2005) and Ca2+/calmodulin-depen-
dent protein kinase II (Wright et al. 2007). It is interesting
to speculate that the exhaustive treadmill exercise elicits
other signals, which are required to synergize with PGC1a
to elicit FNDC5 expression and are not present during the
in situ muscle contraction. It is also possible that the
intensity of contraction used to match force between wild-
type and AMPK DMKO muscle in situ was too low to
drive robust changes in FNDC5 expression. Our data dem-
onstrate that the contraction intensity achieved in our
in situ system was sufficient to activate AMPK in wild-type
muscle while driving PGC1a expression in both wild-type
and AMPK deficient muscle. Despite this substantial acti-
vation of the AMPK-PGC1a axis there was no change in
FNDC5 expression suggesting that other factors may be
required to increase FNDC5 expression during muscle
contractions.
Given the complexities of matching exercise intensities
and muscle force between wild-type and AMPK DMKO
mice we conducted studies with AICAR, which increases
skeletal muscle AMPK activity (Winder and Hardie 1996)
and has shown to increase PGC1a expression via an
AMPKa2 and PGC1a dependent pathway (Jorgensen
et al. 2005). We conducted 2 weeks of daily AICAR treat-
ment and although AICAR elicited the expected phos-
phorylation of ACC2 and reduced blood glucose levels
consistent with the activation of skeletal muscle AMPK
that we (Dzamko et al. 2008; Steinberg et al. 2010) and
others (Barnes et al. 2004; Jorgensen et al. 2004) have
observed, it failed to increase FNDC5 expression. There-
fore, chronic activation of AMPK via AICAR administra-
tion is not sufficient to cause changes in FNDC5
expression in vivo.
Conclusions
This study is the first to find that skeletal muscle AMPK
is required to maintain basal expression of FNDC5 in
skeletal muscle. Neither an acute bout of exhaustive exer-
cise nor force-matched in situ muscle contractions, that
induce comparable increases in AMPK activity, resulted
in increases in FNDC5 expression in either wild-type or
AMPK DMKO mice. Lastly, chronic pharmacological acti-
vation of AMPK using AICAR is insufficient to increase
FNDC5 skeletal muscle. These studies indicate that AMPK
is essential for maintaining basal FNDC5 expression but
that other factors may contribute to increases in FNDC5
during exercise/muscle contractions.
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